The first-in-class tyrosine kinase inhibitor masitinib decreased asthma exacerbations greater than placebo in patients with severe asthma uncontrolled by oral corticosteroids.
In patients with COPD, treatment with single-inhaler fluticasone furoate/umeclidinium/vilanterol resulted in more health status improvements and greater lung function benefit compared with multiple-inhaler triple therapy.
Prenatal and early life exposure to household air pollution may affect the development of lung function and lead to an increase in airway resistance in children.
Compared with white patients, black patients with screen-detected cancers had a lower calculated lung cancer risk, despite having a significantly higher mean 6-year lung cancer risk.
In terms of screening for obstructive sleep apnea in people living with HIV, the STOP-BANG questionnaire had good sensitivity, whereas the Berlin questionnaire and the Epworth Sleepiness Scale demonstrated good specificity.
Patients with severe eosinophilic asthma who are treated with mepolizumab and subsequently stop treatment have increased blood eosinophil counts and increased exacerbations, among other negative clinical outcomes.
